# ISEMBYLD (apitegromab) PDUFA date and FDA approval status

Canonical: https://sec-api.dev/pdufa/apitegromab

> The FDA approved ISEMBYLD (apitegromab), sponsored by Scholar Rock Holding Corp (SRRK), on September 11, 2026 for SMA in adults and children 2 years of age and older.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: month only, exact day, quarter only, year only, half-year only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Verified answer

### Is ISEMBYLD (apitegromab) FDA approved?

Yes. The FDA approved ISEMBYLD (apitegromab), sponsored by Scholar Rock Holding Corp (SRRK), on September 11, 2026 for SMA in adults and children 2 years of age and older. SEC Form 8-K: "On September 11, 2026, the Company announced that the FDA has approved ISEMBYLD™ (apitegromab-mstn) for the treatment of SMA in adults and children 2 years of age and older who are currently receiving a survival SMN2 targeted treatment." [Calendar and source filings](https://sec-api.dev/pdufa/apitegromab)

Source: SEC Form 8-K, accession 0001104659-26-107273, https://www.sec.gov/Archives/edgar/data/1727196/000110465926107273/tm2625362d1_8k.htm (retrieved 2026-11-12). Last confirmed 2026-11-10. Cite: https://sec-api.dev/pdufa/apitegromab#answer

## Key facts

| Field | Value |
| --- | --- |
| Drug | ISEMBYLD (apitegromab) |
| Codes | SRK-015, SRK-439 |
| Sponsor | Scholar Rock Holding Corp (SRRK) https://sec-api.dev/companies/srrk/catalysts |
| Indications | sma, we, non-ambulatory type 2 and type 3 sma, [with type 2 and type 3 sma and in october 2024, we](https://sec-api.dev/indications/with-type-2-and-type-3-sma-and-in-october-2024-we), [obesity](https://sec-api.dev/indications/obesity), children and adults with sma, nonambulatory type 2 and type 3 sma, [Spinal Muscular Atrophy](https://sec-api.dev/indications/spinal-muscular-atrophy), Facioscapulohumeral Muscular Dystrophy |
| Modality | antibody |
| FDA designations | fast track, orphan, priority review |

## Timeline

### Apr 2021: topline data readout

- Status: completed, positive. Date confidence: month.
- First seen 2024-11-12, last confirmed 2024-11-12.
- SEC Form 10-Q (accession 0001558370-24-015155): "Positive 12-month top-line results were initially announced in April 2021." https://www.sec.gov/Archives/edgar/data/1727196/000155837024015155/srrk-20240930x10q.htm

### Jan 2022: trial start

- Status: completed. Date confidence: month. Stage: 3. Indication: with Type 2 and Type 3 SMA and in October 2024, we.
- First seen 2024-11-12, last confirmed 2025-05-14.
- SEC Form 10-Q (accession 0001558370-25-007655): "In January 2022, we initiated our Phase 3 SAPPHIRE clinical trial of apitegromab for the treatment of patients with Type 2 and Type 3 SMA and in October 2024, we announced positive top-line data from our Phase 3 SAPPHIRE clinical trial evaluating the efficacy and safety of apitegromab." https://www.sec.gov/Archives/edgar/data/1727196/000155837025007655/srrk-20250331x10q.htm
- SEC Form 10-K (accession 0001558370-25-001682): "In January 2022, we initiated our Phase 3 SAPPHIRE clinical trial of apitegromab for the treatment of patients with Type 2 and Type 3 SMA and in October 2024, we announced positive top-line data from our Phase 3 SAPPHIRE clinical trial evaluating the efficacy and safety of apitegromab." https://www.sec.gov/Archives/edgar/data/1727196/000155837025001682/srrk-20241231x10k.htm
- SEC Form 10-Q (accession 0001558370-24-015155): "In January 2022, we initiated our Phase 3 SAPPHIRE clinical trial of apitegromab for the treatment of patients with Type 2 and Type 3 SMA and in September 2023, we announced completion of trial enrollment." https://www.sec.gov/Archives/edgar/data/1727196/000155837024015155/srrk-20240930x10q.htm

### Jan 2022: topline data readout

- Status: completed, positive. Date confidence: month. Stage: 3. Indication: with Type 2 and Type 3 SMA and in October 2024, we.
- First seen 2025-02-27, last confirmed 2025-05-14.
- SEC Form 10-Q (accession 0001558370-25-007655): "In January 2022, we initiated our Phase 3 SAPPHIRE clinical trial of apitegromab for the treatment of patients with Type 2 and Type 3 SMA and in October 2024, we announced positive top-line data from our Phase 3 SAPPHIRE clinical trial evaluating the efficacy and safety of apitegromab." https://www.sec.gov/Archives/edgar/data/1727196/000155837025007655/srrk-20250331x10q.htm
- SEC Form 10-K (accession 0001558370-25-001682): "In January 2022, we initiated our Phase 3 SAPPHIRE clinical trial of apitegromab for the treatment of patients with Type 2 and Type 3 SMA and in October 2024, we announced positive top-line data from our Phase 3 SAPPHIRE clinical trial evaluating the efficacy and safety of apitegromab." https://www.sec.gov/Archives/edgar/data/1727196/000155837025001682/srrk-20241231x10k.htm

### Oct 2023: trial start

- Status: completed. Date confidence: month. Stage: 2.
- First seen 2025-05-14, last confirmed 2025-05-14.
- SEC Form 10-Q (accession 0001558370-25-007655): "We also announced in October 2023 our plans to expand into cardiometabolic disorders based on preclinical data with SRK-439, and we initiated the Phase 2 EMBRAZE proof-of-concept trial of" https://www.sec.gov/Archives/edgar/data/1727196/000155837025007655/srrk-20250331x10q.htm

### October 7, 2024: topline data readout

- Status: completed, positive. Date confidence: exact. Stage: 3. Indication: non-ambulatory Type 2 and Type 3 SMA.
- First seen 2024-11-12, last confirmed 2026-08-06.
- SEC Form 10-K (accession 0001104659-26-022551): "On October 7, 2024, we announced positive top-line data from our Phase 3 SAPPHIRE clinical trial evaluating the efficacy and safety of apitegromab in children and adults with SMA." https://www.sec.gov/Archives/edgar/data/1727196/000110465926022551/srrk-20251231x10k.htm
- SEC Form 10-K (accession 0001558370-25-001682): "On October 7, 2024, we announced positive top-line data from our Phase 3 SAPPHIRE clinical trial evaluating the efficacy and safety of apitegromab, an investigational muscle-targeted therapy, in patients with SMA." https://www.sec.gov/Archives/edgar/data/1727196/000155837025001682/srrk-20241231x10k.htm
- SEC Form 10-Q (accession 0001558370-24-015155): "On October 7, 2024, we announced positive top-line data from our Phase 3 SAPPHIRE clinical trial evaluating the efficacy and safety of apitegromab, an investigational muscle-targeted therapy, in patients with SMA." https://www.sec.gov/Archives/edgar/data/1727196/000155837024015155/srrk-20240930x10q.htm
- SEC prospectus (424B) (accession 0001104659-26-091699): "In October 2024, we announced positive top-line results in SAPPHIRE, a pivotal Phase 3 clinical trial to evaluate the efficacy and safety of apitegromab in patients with non-ambulatory Type 2 and Type 3 SMA (which is estimated to represent the majority of the current prevalent SMA patient population in the U.S. and Europe)." https://www.sec.gov/Archives/edgar/data/1727196/000110465926091699/tm2622083-1_424b5.htm
- SEC Form 10-Q (accession 0001193125-26-336732): "In October 2024, we announced positive top-line results in SAPPHIRE, a pivotal Phase 3 clinical trial to evaluate the efficacy and safety of apitegromab in patients with non-ambulatory Type 2 and Type 3 SMA (which is estimated to represent the majority of the current prevalent SMA patient population in the U.S. and Europe)." https://www.sec.gov/Archives/edgar/data/1727196/000119312526336732/srrk-20260630.htm
- SEC Form 10-Q (accession 0001104659-26-056667): "In October 2024, we announced positive top-line results in SAPPHIRE, a pivotal Phase 3 clinical trial to evaluate the efficacy and safety of apitegromab in patients with non-ambulatory Type 2 and Type 3 SMA (which is estimated to represent the majority of the current prevalent SMA patient population in the U.S. and Europe)." https://www.sec.gov/Archives/edgar/data/1727196/000110465926056667/srrk-20260331x10q.htm
- SEC Form 10-K (accession 0001104659-26-022551): "In October 2024, we announced positive top-line results in SAPPHIRE, a pivotal Phase 3 clinical trial to evaluate the efficacy and safety of apitegromab in patients with non-ambulatory Type 2 and Type 3 SMA (which is estimated to represent the majority of the current prevalent SMA patient population in the U.S. and Europe)." https://www.sec.gov/Archives/edgar/data/1727196/000110465926022551/srrk-20251231x10k.htm
- SEC Form 10-Q (accession 0001104659-25-111935): "In October 2024, the Company announced positive top-line results from SAPPHIRE, a pivotal Phase 3 clinical trial to evaluate the efficacy and safety of apitegromab in patients with non-ambulatory SMA." https://www.sec.gov/Archives/edgar/data/1727196/000110465925111935/srrk-20250930x10q.htm
- SEC Form 10-Q (accession 0001104659-25-111935): "In October 2024, we announced positive top-line results in SAPPHIRE, a pivotal Phase 3 clinical trial to evaluate the efficacy and safety of apitegromab in patients with non-ambulatory Type 2 and Type 3 SMA (which is estimated to represent the majority of the current prevalent SMA patient population in the U.S. and Europe)." https://www.sec.gov/Archives/edgar/data/1727196/000110465925111935/srrk-20250930x10q.htm
- SEC Form 10-Q (accession 0001104659-25-111935): "Our Phase 3 SAPPHIRE clinical trial evaluated the safety and efficacy of apitegromab for the treatment of patients with Type 2 and Type 3 SMA and in October 2024, we announced positive top-line data from this clinical trial." https://www.sec.gov/Archives/edgar/data/1727196/000110465925111935/srrk-20250930x10q.htm
- SEC prospectus (424B) (accession 0001104659-25-111955): "In October 2024, we announced positive top-line results in SAPPHIRE, a pivotal Phase 3 clinical trial to evaluate the efficacy and safety of apitegromab in patients with non-ambulatory Type 2 and Type 3 SMA (which is estimated to represent the majority of the current prevalent SMA patient population in the U.S. and Europe)." https://www.sec.gov/Archives/edgar/data/1727196/000110465925111955/tm2530774-1_424b5.htm
- SEC Form 10-Q (accession 0001558370-25-010400): "In October 2024, the Company announced positive top-line results from SAPPHIRE, a pivotal Phase 3 clinical trial to evaluate the efficacy and safety of apitegromab in patients with non-ambulatory SMA." https://www.sec.gov/Archives/edgar/data/1727196/000155837025010400/srrk-20250630x10q.htm

### Jan 2025: NDA/BLA submission

- Status: completed. Date confidence: month. Indication: SMA, we.
- First seen 2025-02-27, last confirmed 2026-11-10.
- SEC Form 10-Q (accession 0001193125-26-454434): "Prior to submitting the BLA to the U.S. FDA in January 2025 and submitting the MAA to the EMA in March 2025 for apitegromab as a treatment for patients with SMA, we had not submitted a BLA to the FDA or MAA to the EMA or similar marketing application to comparable foreign authorities." https://www.sec.gov/Archives/edgar/data/1727196/000119312526454434/srrk-20260930.htm
- SEC Form 10-Q (accession 0001193125-26-336732): "Prior to submitting the BLA to the U.S. FDA in January 2025 and submitting the MAA to the EMA in March 2025 for apitegromab as a treatment for patients with SMA, we had not submitted a BLA to the FDA or MAA to the EMA or similar marketing application to comparable foreign authorities." https://www.sec.gov/Archives/edgar/data/1727196/000119312526336732/srrk-20260630.htm
- SEC Form 10-Q (accession 0001104659-26-056667): "Prior to submitting the BLA to the U.S. FDA in January 2025 and submitting the MAA to the EMA in March 2025 for apitegromab as a treatment for patients with SMA, we had not submitted a BLA to the FDA or MAA to the EMA or similar marketing application to comparable foreign authorities." https://www.sec.gov/Archives/edgar/data/1727196/000110465926056667/srrk-20260331x10q.htm
- SEC Form 10-K (accession 0001104659-26-022551): "Following a successful clinical development program, we submitted a BLA for apitegromab for the treatment of children and adults with SMA to the FDA in January 2025 and the BLA was granted priority review designation." https://www.sec.gov/Archives/edgar/data/1727196/000110465926022551/srrk-20251231x10k.htm
- SEC Form 10-K (accession 0001104659-26-022551): "Prior to submitting the BLA to the U.S. FDA in January 2025 and submitting the MAA to the EMA in March 2025 for apitegromab as a treatment for patients with SMA, we had not submitted a BLA to the FDA or MAA to the EMA or similar marketing application to comparable foreign authorities." https://www.sec.gov/Archives/edgar/data/1727196/000110465926022551/srrk-20251231x10k.htm
- SEC Form 10-Q (accession 0001104659-25-111935): "Prior to filing the BLA to the U.S. FDA in January 2025 and submitting the MAA to the EMA in March 2025 for apitegromab as a treatment for patients with SMA, we have not submitted a BLA to the FDA or MAA to the EMA or similar marketing application to comparable foreign authorities." https://www.sec.gov/Archives/edgar/data/1727196/000110465925111935/srrk-20250930x10q.htm
- SEC Form 10-Q (accession 0001558370-25-010400): "Prior to filing the BLA to the U.S. FDA in January 2025 and submitting the MAA to the EMA in March 2025 for apitegromab as a treatment for patients with SMA, we have not submitted a BLA to the FDA or MAA to the EMA or similar marketing application to comparable foreign authorities." https://www.sec.gov/Archives/edgar/data/1727196/000155837025010400/srrk-20250630x10q.htm
- SEC Form 10-Q (accession 0001558370-25-007655): "Prior to filing the BLA to the U.S. FDA in January 2025 and submitting the MAA to the EMA in March 2025 for apitegromab as a treatment for patients with SMA, we have not submitted a BLA to the FDA or MAA to the EMA or similar marketing application to comparable foreign authorities." https://www.sec.gov/Archives/edgar/data/1727196/000155837025007655/srrk-20250331x10q.htm
- SEC Form 10-K (accession 0001558370-25-001682): "Prior to filing the Biologics License Application ("BLA") to the U.S. FDA for apitegromab as a treatment for patients with SMA in January 2025, we have not submitted a BLA to the FDA or similar marketing application to comparable foreign authorities." https://www.sec.gov/Archives/edgar/data/1727196/000155837025001682/srrk-20241231x10k.htm
- SEC Form 10-K (accession 0001558370-25-001682): "We submitted a BLA to the FDA in January 2025 and requested priority review, and we plan to submit a marketing authorization application to the EMA in the first quarter of 2025." https://www.sec.gov/Archives/edgar/data/1727196/000155837025001682/srrk-20241231x10k.htm

### Q1 2025: NDA/BLA submission

- Status: scheduled. Date confidence: quarter.
- First seen 2024-11-12, last confirmed 2024-11-12.
- Press release filed with the SEC (EX-99) (accession 0001558370-24-015149): "Based on these results, we plan to submit a BLA and MAA in the first quarter of 2025 and are working diligently to prepare for the commercial launch of apitegromab, and if approved, to deliver the potentially transformative benefits of apitegromab to children and adults living with SMA."" https://www.sec.gov/Archives/edgar/data/1727196/000155837024015149/srrk-20241112xex99d1.htm

### Mar 2025: NDA/BLA acceptance

- Status: completed. Date confidence: month.
- First seen 2025-05-14, last confirmed 2025-05-14.
- Press release filed with the SEC (EX-99) (accession 0001558370-25-007650): "In March 2025, the FDA accepted the Company's BLA for apitegromab for people with SMA and granted the application Priority Review with a" https://www.sec.gov/Archives/edgar/data/1727196/000155837025007650/srrk-20250514xex99d1.htm

### Q2 2025: interim data readout

- Status: scheduled. Date confidence: quarter.
- First seen 2024-11-12, last confirmed 2024-11-12.
- Press release filed with the SEC (EX-99) (accession 0001558370-24-015149): "Enrollment completed early with topline expected in Q2 2025" https://www.sec.gov/Archives/edgar/data/1727196/000155837024015149/srrk-20241112xex99d2.htm

### June 18, 2025: topline data readout

- Status: completed, positive. Date confidence: exact. Stage: 2. Indication: obesity receiving tirzepatide.
- First seen 2024-11-12, last confirmed 2026-03-03.
- SEC Form 10-Q (accession 0001558370-25-010400): "On June 18, 2025, we announced positive top-line data from our Phase 2 EMBRAZE clinical trial evaluating apitegromab, an investigational muscle-targeted treatment, with tirzepatide to preserve lean mass during tirzepatide-induced weight loss." https://www.sec.gov/Archives/edgar/data/1727196/000155837025010400/srrk-20250630x10q.htm
- SEC Form 10-Q (accession 0001104659-25-111935): "In June 2025, the Company announced positive top-line results from the Phase 2 EMBRAZE proof-of-concept trial, designed to assess the safety and efficacy of apitegromab to preserve lean mass in individuals living with obesity and on background therapy of a GLP-1 RA (tirzepatide)." https://www.sec.gov/Archives/edgar/data/1727196/000110465925111935/srrk-20250930x10q.htm
- SEC prospectus (424B) (accession 0001104659-25-111955): "In June 2025, the Company announced positive top-line results from the Phase 2 EMBRAZE proof-of-concept trial, designed to assess the safety and efficacy of apitegromab to preserve lean mass in individuals living with obesity and on background therapy of a GLP-1 RA (tirzepatide)." https://www.sec.gov/Archives/edgar/data/1727196/000110465925111955/tm2530774-1_424b5.htm
- SEC Form 10-Q (accession 0001558370-25-010400): "In June 2025, the Company announced positive top-line results from the Phase 2 EMBRAZE proof-of-concept trial, designed to assess the safety and efficacy of apitegromab to preserve lean mass in individuals living with obesity and on background therapy of a GLP-1 RA (tirzepatide)." https://www.sec.gov/Archives/edgar/data/1727196/000155837025010400/srrk-20250630x10q.htm
- SEC Form 10-Q (accession 0001558370-25-007655): "Table of Contents apitegromab in combination with a GLP-1 RA in obesity in May 2024 with top-line results expected in the second quarter of 2025." https://www.sec.gov/Archives/edgar/data/1727196/000155837025007655/srrk-20250331x10q.htm
- Press release filed with the SEC (EX-99) (accession 0001558370-25-001681): "- Topline data from Phase 2 EMBRAZE trial evaluating apitegromab vs placebo in adult patients with obesity receiving tirzepatide expected in 2Q 2025" https://www.sec.gov/Archives/edgar/data/1727196/000155837025001681/srrk-20250227xex99d1.htm
- Press release filed with the SEC (EX-99) (accession 0001558370-24-015149): "- Phase 2 EMBRAZE trial enrollment completed for apitegromab in obesity with topline data expected in 2Q 2025" https://www.sec.gov/Archives/edgar/data/1727196/000155837024015149/srrk-20241112xex99d1.htm
- Press release filed with the SEC (EX-99) (accession 0001558370-25-007650): "Topline results from Phase 2 EMBRAZE proof-of-concept trial in adult patients with obesity on track for June 2025" https://www.sec.gov/Archives/edgar/data/1727196/000155837025007650/srrk-20250514xex99d1.htm
- SEC Form 10-K (accession 0001558370-25-001682): "We also announced in October 2023 our plans to expand into cardiometabolic disorders based on preclinical data with SRK-439, and we initiated the Phase 2 EMBRAZE proof-of-concept trial of apitegromab in combination with a GLP-1 RA in obesity in May 2024 with top-line results expected in the second quarter of 2025." https://www.sec.gov/Archives/edgar/data/1727196/000155837025001682/srrk-20241231x10k.htm
- SEC Form 10-Q (accession 0001558370-24-015155): "We also announced in October 2023 our plans to expand into cardiometabolic disorders based on preclinical data with SRK-439, and we initiated the Phase 2 EMBRAZE proof-of-concept trial of apitegromab in combination with a GLP-1 receptor agonist in obesity in May 2024 with top-line results expected in the second quarter of 2025." https://www.sec.gov/Archives/edgar/data/1727196/000155837024015155/srrk-20240930x10q.htm
- Press release filed with the SEC (EX-99) (accession 0001558370-25-001681): "Topline data expected in the second quarter of 2025 from the Phase 2 EMBRAZE proof-of-concept trial." https://www.sec.gov/Archives/edgar/data/1727196/000155837025001681/srrk-20250227xex99d1.htm
- SEC Form 10-K (accession 0001104659-26-022551): "In June 2025, we announced positive topline data from this study that showed significant preservation of lean mass with apitegromab during tirzepatide-induced weight loss." https://www.sec.gov/Archives/edgar/data/1727196/000110465926022551/srrk-20251231x10k.htm

### Q3 2025: trial start

- Status: scheduled. Date confidence: quarter. Stage: 2.
- First seen 2025-05-14, last confirmed 2025-08-06.
- SEC Form 10-Q (accession 0001558370-25-010400): "The Company continues to develop apitegromab in SMA with its ongoing long-term extension ONYX trial and its plan to initiate the Phase 2 OPAL trial in SMA patients under two years of age in the third quarter of 2025." https://www.sec.gov/Archives/edgar/data/1727196/000155837025010400/srrk-20250630x10q.htm
- Press release filed with the SEC (EX-99) (accession 0001558370-25-010399): "Expect to initiate the Phase 2 OPAL clinical trial in SMA in Q3 2025." https://www.sec.gov/Archives/edgar/data/1727196/000155837025010399/srrk-20250806xex99d1.htm
- Press release filed with the SEC (EX-99) (accession 0001558370-25-007650): "Expect to initiate the Phase 2 OPAL clinical trial in SMA in Q3 2025." https://www.sec.gov/Archives/edgar/data/1727196/000155837025007650/srrk-20250514xex99d1.htm

### Sep 2025: NDA/BLA acceptance

- Status: completed. Date confidence: month.
- First seen 2026-05-07, last confirmed 2026-08-06.
- SEC Form 10-Q (accession 0001193125-26-336732): "We received a CRL from the FDA in September 2025 and in March 2026 we resubmitted the apitegromab BLA which was accepted by the FDA." https://www.sec.gov/Archives/edgar/data/1727196/000119312526336732/srrk-20260630.htm
- SEC Form 10-Q (accession 0001104659-26-056667): "We received a CRL from the FDA in September 2025 and in March 2026 we resubmitted the apitegromab BLA which was accepted by the FDA." https://www.sec.gov/Archives/edgar/data/1727196/000110465926056667/srrk-20260331x10q.htm

### September 22, 2025: PDUFA date

- Status: completed, complete response letter. Date confidence: exact. Indication: Spinal Muscular Atrophy.
- First seen 2025-05-14, last confirmed 2025-08-06.
- Press release filed with the SEC (EX-99) (accession 0001558370-25-010399): "Exhibit 99.1 target action date for apitegromab of September 22, 2025." https://www.sec.gov/Archives/edgar/data/1727196/000155837025010399/srrk-20250806xex99d1.htm
- Press release filed with the SEC (EX-99) (accession 0001558370-25-007650): "Apitegromab BLA accepted under priority review for patients with Spinal Muscular Atrophy (SMA) and FDA's PDUFA date set for September 22, 2025; commercial readiness progresses" https://www.sec.gov/Archives/edgar/data/1727196/000155837025007650/srrk-20250514xex99d1.htm
- Press release filed with the SEC (EX-99) (accession 0001558370-25-007650): "Prescription Drug User Fee Act (PDUFA) target action date of September 22, 2025." https://www.sec.gov/Archives/edgar/data/1727196/000155837025007650/srrk-20250514xex99d1.htm
- SEC Form 10-Q (accession 0001558370-25-010400): "The Company submitted a U.S. Biologics License Application ("BLA") to the FDA in January 2025, which is now under priority review with a Prescription Drug User Fee Act ("PDUFA") target action date of September 22, 2025." https://www.sec.gov/Archives/edgar/data/1727196/000155837025010400/srrk-20250630x10q.htm
- SEC Form 10-Q (accession 0001558370-25-010400): "We submitted a U.S. Biologics License Application to the FDA in January 2025, which is now under priority review with a PDUFA target action date of September 22, 2025." https://www.sec.gov/Archives/edgar/data/1727196/000155837025010400/srrk-20250630x10q.htm
- SEC Form 10-Q (accession 0001558370-25-007655): "The Company submitted a U.S. Biologics License Application ("BLA") to the FDA in January 2025, which is now under priority review with a Prescription Drug User Fee Act ("PDUFA") target action date of September 22, 2025." https://www.sec.gov/Archives/edgar/data/1727196/000155837025007655/srrk-20250331x10q.htm
- SEC Form 10-Q (accession 0001558370-25-007655): "We submitted a U.S. Biologics License Application to the FDA in January 2025, which is now under priority review with a Prescription Drug User Fee Act ("PDUFA") target action date of September 22, 2025." https://www.sec.gov/Archives/edgar/data/1727196/000155837025007655/srrk-20250331x10q.htm
- SEC Form 8-K (accession 0001104659-25-092317): "On September 23, 2025, the Company announced that the FDA has issued a CRL regarding the BLA for apitegromab for the treatment of SMA." https://www.sec.gov/Archives/edgar/data/1727196/000110465925092317/tm2526733d1_8k.htm

### September 23, 2025: complete response letter (CRL)

- Status: completed, complete response letter. Date confidence: exact.
- First seen 2025-09-23, last confirmed 2026-11-10.
- SEC Form 8-K (accession 0001104659-25-092317): "On September 23, 2025, the Company announced that the FDA has issued a CRL regarding the BLA for apitegromab for the treatment of SMA." https://www.sec.gov/Archives/edgar/data/1727196/000110465925092317/tm2526733d1_8k.htm
- Press release filed with the SEC (EX-99) (accession 0001104659-26-037350): "In September 2025, Scholar Rock received a Complete Response Letter (CRL) from the FDA for apitegromab related to observations identified during a routine general site inspection of Catalent Indiana, LLC (part of Novo Nordisk)." https://www.sec.gov/Archives/edgar/data/1727196/000110465926037350/tm2610664d1_ex99-1.htm
- SEC Form 10-Q (accession 0001193125-26-454434): "For example, in September 2025, we received a CRL from the FDA citing observations identified during an FDA inspection of a third-party fill-finish facility used in our BLA and MAA for apitegromab." https://www.sec.gov/Archives/edgar/data/1727196/000119312526454434/srrk-20260930.htm
- SEC Form 10-Q (accession 0001193125-26-336732): "We received a CRL from the FDA in September 2025 and in March 2026 we resubmitted the apitegromab BLA which was accepted by the FDA." https://www.sec.gov/Archives/edgar/data/1727196/000119312526336732/srrk-20260630.htm
- SEC Form 10-Q (accession 0001193125-26-336732): "In September 2025, we received a CRL from the FDA for the apitegromab BLA citing observations identified during an FDA inspection of a third-party fill-finish facility." https://www.sec.gov/Archives/edgar/data/1727196/000119312526336732/srrk-20260630.htm
- SEC Form 10-Q (accession 0001104659-26-056667): "We received a CRL from the FDA in September 2025 and in March 2026 we resubmitted the apitegromab BLA which was accepted by the FDA." https://www.sec.gov/Archives/edgar/data/1727196/000110465926056667/srrk-20260331x10q.htm
- SEC Form 10-Q (accession 0001104659-26-056667): "In September 2025, we received a CRL from the FDA for the apitegromab BLA citing observations identified during an FDA inspection of a third-party fill-finish facility." https://www.sec.gov/Archives/edgar/data/1727196/000110465926056667/srrk-20260331x10q.htm
- SEC Form 10-K (accession 0001104659-26-022551): "The CRL received from the FDA in September 2025 will require us to resubmit the apitegromab BLA and our progress toward potential commercialization of apitegromab has been delayed." https://www.sec.gov/Archives/edgar/data/1727196/000110465926022551/srrk-20251231x10k.htm
- SEC Form 10-K (accession 0001104659-26-022551): "In September 2025, we received a CRL from the FDA for the apitegromab BLA citing observations identified during an FDA inspection of a third-party fill-finish facility." https://www.sec.gov/Archives/edgar/data/1727196/000110465926022551/srrk-20251231x10k.htm
- SEC Form 10-Q (accession 0001104659-25-111935): "In September 2025, we received a CRL from the FDA for the apitegromab BLA related to observations identified during a routine general site inspection of a third-party fill-finish facility." https://www.sec.gov/Archives/edgar/data/1727196/000110465925111935/srrk-20250930x10q.htm
- SEC prospectus (424B) (accession 0001104659-26-091699): "In September 2025, we received a CRL from the FDA related to observations identified during an FDA site inspection of a third-party fill-finish facility." https://www.sec.gov/Archives/edgar/data/1727196/000110465926091699/tm2622083-1_424b5.htm
- SEC Form 10-Q (accession 0001193125-26-336732): "In September 2025, the Company received a Complete Response Letter ("CRL") from the FDA related to observations identified during an FDA inspection of a third-party fill-finish facility." https://www.sec.gov/Archives/edgar/data/1727196/000119312526336732/srrk-20260630.htm

### Dec 2025: trial start

- Status: completed. Date confidence: month. Stage: 1.
- First seen 2026-01-12, last confirmed 2026-01-12.
- Press release filed with the SEC (EX-99) (accession 0001104659-26-002757): "Dosing commenced in Phase 1 study in December 2025" https://www.sec.gov/Archives/edgar/data/1727196/000110465926002757/srrk-20260112xex99d2.htm

### 2026: NDA/BLA submission

- Status: scheduled. Date confidence: year.
- First seen 2026-01-12, last confirmed 2026-01-12.
- Press release filed with the SEC (EX-99) (accession 0001104659-26-002757): "Apitegromab BLA resubmission and U.S. launch, following approval, anticipated in 2026" https://www.sec.gov/Archives/edgar/data/1727196/000110465926002757/srrk-20260112xex99d2.htm

### March 31, 2026: NDA/BLA submission

- Status: completed. Date confidence: exact. Indication: children and adults with SMA.
- First seen 2026-03-31, last confirmed 2026-03-31.
- SEC Form 8-K (accession 0001104659-26-037350): "On March 31, 2026, Scholar Rock Holding Corporation (the "Company") issued a press release announcing it resubmitted its biologics license application ("BLA") to the U.S. Food and Drug Administration (the "FDA") for apitegromab for the treatment of children and adults with spinal muscular atrophy ("SMA")." https://www.sec.gov/Archives/edgar/data/1727196/000110465926037350/tm2610664d1_8k.htm
- SEC Form 8-K (accession 0001104659-26-037350): "On March 31, 2026, the Company announced that it resubmitted its BLA to the FDA for apitegromab for the treatment of children and adults with SMA." https://www.sec.gov/Archives/edgar/data/1727196/000110465926037350/tm2610664d1_8k.htm
- Press release filed with the SEC (EX-99) (accession 0001104659-26-037350): "Rock (NASDAQ: SRRK), a global biopharmaceutical company dedicated to improving the lives of children and adults with spinal muscular atrophy (SMA) and additional rare, severe, and debilitating neuromuscular diseases by applying its leading platform in myostatin biology to advance musculoskeletal health, today announced it has resubmitted the Biologics License Application (BLA) for apitegromab for the treatment of children and adults with SMA to the U.S. Food and Drug Administration (FDA)." https://www.sec.gov/Archives/edgar/data/1727196/000110465926037350/tm2610664d1_ex99-1.htm

### mid-2026: trial start

- Status: scheduled. Date confidence: half. Stage: 2.
- First seen 2026-01-12, last confirmed 2026-03-03.
- Press release filed with the SEC (EX-99) (accession 0001104659-26-022547): "The IND application is cleared, and the Company continues to anticipate the initiation of a Phase 2 randomized, double-blind, placebo-controlled trial, called FORGE, in mid-2026." https://www.sec.gov/Archives/edgar/data/1727196/000110465926022547/srrk-20260303xex99d1.htm
- Press release filed with the SEC (EX-99) (accession 0001104659-26-002757): "IND application cleared; on track to initiate dosing in Phase 2 FORGE study in mid-2026" https://www.sec.gov/Archives/edgar/data/1727196/000110465926002757/srrk-20260112xex99d2.htm

### September 11, 2026: FDA approval

- Status: completed, approved. Date confidence: exact. Indication: SMA in adults and children 2 years of age and older.
- First seen 2026-09-14, last confirmed 2026-11-10.
- SEC Form 8-K (accession 0001104659-26-107273): "On September 11, 2026, the Company announced that the FDA has approved ISEMBYLD™ (apitegromab-mstn) for the treatment of SMA in adults and children 2 years of age and older who are currently receiving a survival SMN2 targeted treatment." https://www.sec.gov/Archives/edgar/data/1727196/000110465926107273/tm2625362d1_8k.htm
- Press release filed with the SEC (EX-99) (accession 0001193125-26-454423): "Following the September 11, 2026 FDA approval of ISEMBYLD, the Company is engaging with regulators on the development path for this formulation." https://www.sec.gov/Archives/edgar/data/1727196/000119312526454423/srrk-ex99_1.htm
- Press release filed with the SEC (EX-99) (accession 0001193125-26-454423): "The PRV was awarded following the September 2026 FDA approval of ISEMBYLD." https://www.sec.gov/Archives/edgar/data/1727196/000119312526454423/srrk-ex99_1.htm

### September 30, 2026: PDUFA date

- Status: completed, approved. Date confidence: exact.
- First seen 2026-03-31, last confirmed 2026-08-06.
- Press release filed with the SEC (EX-99) (accession 0001193125-26-336715): "Apitegromab Biologics License Application (BLA) for spinal muscular atrophy (SMA) review by FDA continues to advance with two fill-finish facilities, representing two independent paths to an FDA approval decision by September 30, 2026 Prescription Drug User Fee Act (PDUFA) date" https://www.sec.gov/Archives/edgar/data/1727196/000119312526336715/srrk-ex99_1.htm
- Press release filed with the SEC (EX-99) (accession 0001193125-26-336715): "the expected timing and outcome of FDA review of the accepted BLA for apitegromab, including the September 30, 2026 PDUFA action date" https://www.sec.gov/Archives/edgar/data/1727196/000119312526336715/srrk-ex99_1.htm
- Press release filed with the SEC (EX-99) (accession 0001104659-26-056655): "Apitegromab BLA accepted by FDA with September 30, 2026 PDUFA action date." https://www.sec.gov/Archives/edgar/data/1727196/000110465926056655/srrk-20260507xex99d1.htm
- Press release filed with the SEC (EX-99) (accession 0001104659-26-056655): "the expected timing and outcome of FDA review of the accepted BLA for apitegromab, including the September 30, 2026 PDUFA action date;" https://www.sec.gov/Archives/edgar/data/1727196/000110465926056655/srrk-20260507xex99d1.htm
- SEC prospectus (424B) (accession 0001104659-26-091699): "We resubmitted the apitegromab BLA in March 2026 with two third-party fill-finish facilities included, which was accepted by the Agency with a September 30, 2026 Prescription Drug User Fee Act ("PDUFA") action date." https://www.sec.gov/Archives/edgar/data/1727196/000110465926091699/tm2622083-1_424b5.htm
- SEC Form 10-Q (accession 0001193125-26-336732): "The Company resubmitted the apitegromab BLA in March 2026 with two fill-finish facilities included, which was accepted by the FDA with a September 30, 2026 Prescription Drug User Fee Act ("PDUFA") action date." https://www.sec.gov/Archives/edgar/data/1727196/000119312526336732/srrk-20260630.htm
- SEC Form 10-Q (accession 0001193125-26-336732): "We resubmitted the apitegromab BLA in March 2026 with two third-party fill-finish facilities included, which was accepted by the FDA with a September 30, 2026 Prescription Drug User Fee Act ("PDUFA") action date." https://www.sec.gov/Archives/edgar/data/1727196/000119312526336732/srrk-20260630.htm
- SEC Form 10-Q (accession 0001193125-26-336732): "We resubmitted the apitegromab BLA in March 2026 with two third-party fill-finish facilities included, which was accepted by the Agency with a September 30, 2026 PDUFA action date." https://www.sec.gov/Archives/edgar/data/1727196/000119312526336732/srrk-20260630.htm
- SEC Form 10-Q (accession 0001104659-26-056667): "The Company resubmitted the apitegromab BLA in March 2026 with two fill-finish facilities included, which was accepted by the Agency with a September 30, 2026 Prescription Drug User Fee Act ("PDUFA") action date." https://www.sec.gov/Archives/edgar/data/1727196/000110465926056667/srrk-20260331x10q.htm
- SEC Form 10-Q (accession 0001104659-26-056667): "We resubmitted the apitegromab BLA in March 2026 with two third-party fill-finish facilities included, which was accepted by the Agency with a September 30, 2026 Prescription Drug User Fee Act ("PDUFA") action date." https://www.sec.gov/Archives/edgar/data/1727196/000110465926056667/srrk-20260331x10q.htm
- SEC Form 10-Q (accession 0001104659-26-056667): "We resubmitted the apitegromab BLA in March 2026 with two third-party fill-finish facilities included, which was accepted by the Agency with a September 30, 2026 PDUFA action date." https://www.sec.gov/Archives/edgar/data/1727196/000110465926056667/srrk-20260331x10q.htm
- SEC Form 8-K (accession 0001104659-26-037350): "Act ("PDUFA") action date expected in late September 2026." https://www.sec.gov/Archives/edgar/data/1727196/000110465926037350/tm2610664d1_8k.htm

### November 2026: primary completion

- Status: scheduled. Date confidence: month. Stage: 3. Indication: Spinal Muscular Atrophy; Spinal Muscular Atrophy Type 3; Spinal Muscular Atrophy Type 2.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT05626855 (Long-Term Safety & Efficacy of Apitegromab in Patients With SMA Who Completed Previous Trials of Apitegromab): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-11-01 (ESTIMATED); Lead Sponsor Scholar Rock, Inc.." https://clinicaltrials.gov/study/NCT05626855

### Nov 2026 to Feb 2027: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 3. Indication: Spinal Muscular Atrophy; Spinal Muscular Atrophy Type 3; Spinal Muscular Atrophy Type 2.
- First seen 2026-01-12, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT05626855 (Long-Term Safety & Efficacy of Apitegromab in Patients With SMA Who Completed Previous Trials of Apitegromab): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-11-01 (ESTIMATED); Lead Sponsor Scholar Rock, Inc.." https://clinicaltrials.gov/study/NCT05626855
- Press release filed with the SEC (EX-99) (accession 0001193125-26-336715): "A Phase 1 study evaluating SRK-439 in healthy volunteers is progressing well with topline data anticipated in late 2026." https://www.sec.gov/Archives/edgar/data/1727196/000119312526336715/srrk-ex99_1.htm
- Press release filed with the SEC (EX-99) (accession 0001104659-26-056655): "A Phase 1 study evaluating SRK-439 in healthy volunteers is underway, with topline data expected in the second half of 2026." https://www.sec.gov/Archives/edgar/data/1727196/000110465926056655/srrk-20260507xex99d1.htm
- Press release filed with the SEC (EX-99) (accession 0001104659-26-056655): "SRK-439 Healthy Volunteers Phase 1 study topline results expected in H2 2026" https://www.sec.gov/Archives/edgar/data/1727196/000110465926056655/srrk-20260507xex99d2.htm
- Press release filed with the SEC (EX-99) (accession 0001104659-26-022547): "A Phase 1 study evaluating SRK-439 in healthy volunteers is underway, with topline data expected in the second half of 2026." https://www.sec.gov/Archives/edgar/data/1727196/000110465926022547/srrk-20260303xex99d1.htm
- Press release filed with the SEC (EX-99) (accession 0001104659-26-002757): "SRK-439 Phase 1 trial ongoing in healthy volunteers; topline data expected in H2 2026" https://www.sec.gov/Archives/edgar/data/1727196/000110465926002757/srrk-20260112xex99d1.htm
- SEC prospectus (424B) (accession 0001104659-26-091699): "A Phase 1 study of SRK-439 in healthy volunteers is currently underway, with topline data anticipated in the second half of 2026." https://www.sec.gov/Archives/edgar/data/1727196/000110465926091699/tm2622083-1_424b5.htm
- SEC Form 10-Q (accession 0001193125-26-336732): "A Phase 1 study of SRK-439 in healthy volunteers is currently underway, with topline data anticipated in the second half of 2026." https://www.sec.gov/Archives/edgar/data/1727196/000119312526336732/srrk-20260630.htm
- SEC Form 10-Q (accession 0001104659-26-056667): "A Phase 1 study of SRK-439 in healthy volunteers is currently underway, with topline data anticipated in the second half of 2026." https://www.sec.gov/Archives/edgar/data/1727196/000110465926056667/srrk-20260331x10q.htm
- SEC Form 10-K (accession 0001104659-26-022551): "A Phase 1 study of SRK-439 in healthy volunteers is currently underway, with topline data anticipated in the second half of 2026." https://www.sec.gov/Archives/edgar/data/1727196/000110465926022551/srrk-20251231x10k.htm
- Press release filed with the SEC (EX-99) (accession 0001104659-26-002757): "A Phase 1 study in healthy volunteers is underway, and topline data are expected in the second half of 2026." https://www.sec.gov/Archives/edgar/data/1727196/000110465926002757/srrk-20260112xex99d1.htm
- Press release filed with the SEC (EX-99) (accession 0001104659-26-056655): "Phase 1 study in healthy volunteers in progress; topline data expected in H2 2026" https://www.sec.gov/Archives/edgar/data/1727196/000110465926056655/srrk-20260507xex99d2.htm

### June 2028: primary completion

- Status: scheduled. Date confidence: month. Stage: 2. Indication: Facioscapulohumeral Muscular Dystrophy; FSHD.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT07435129 (Phase 2 Study Evaluating Apitegromab for the Treatment of FSHD): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2028-06 (ESTIMATED); Lead Sponsor Scholar Rock, Inc.." https://clinicaltrials.gov/study/NCT07435129

### Jun to Sep 2028: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 2. Indication: Facioscapulohumeral Muscular Dystrophy; FSHD.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT07435129 (Phase 2 Study Evaluating Apitegromab for the Treatment of FSHD): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2028-06 (ESTIMATED); Lead Sponsor Scholar Rock, Inc.." https://clinicaltrials.gov/study/NCT07435129

### November 2028: primary completion

- Status: scheduled. Date confidence: month. Stage: 2. Indication: Spinal Muscular Atrophy; SMA; Spinal Muscular Atrophy Type 2.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT07047144 (A Study to Evaluate How Apitegromab Works in Subjects Who Are Less Than 2 Years Old and Have Spinal Muscular Atrophy): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2028-11 (ESTIMATED); Lead Sponsor Scholar Rock, Inc.." https://clinicaltrials.gov/study/NCT07047144

### Nov 2028 to Feb 2029: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 2. Indication: Spinal Muscular Atrophy; SMA; Spinal Muscular Atrophy Type 2.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT07047144 (A Study to Evaluate How Apitegromab Works in Subjects Who Are Less Than 2 Years Old and Have Spinal Muscular Atrophy): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2028-11 (ESTIMATED); Lead Sponsor Scholar Rock, Inc.." https://clinicaltrials.gov/study/NCT07047144

## Same indication

- [CRB-913](https://sec-api.dev/pdufa/crb-913) (CRBP)
- [DA-1726](https://sec-api.dev/pdufa/da-1726) (MTVA)
- [SPINRAZA (nusinersen)](https://sec-api.dev/pdufa/nusinersen) (BIIB)
- [RT-114](https://sec-api.dev/pdufa/rt-114) (RANI)
- [RaniPill (RT-116)](https://sec-api.dev/pdufa/rt-116) (RANI)
- [Salanersen](https://sec-api.dev/pdufa/salanersen) (BIIB)
- [Wegovy (semaglutide)](https://sec-api.dev/pdufa/semaglutide) (NVO)
- [VK2735](https://sec-api.dev/pdufa/vk2735) (VKTX)
- [WVE-007](https://sec-api.dev/pdufa/wve-007) (WVE)

Calendar months: [November 2026](https://sec-api.dev/fda-calendar/2026-11)

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/pdufa/apitegromab.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "ISEMBYLD (apitegromab) PDUFA date and FDA approval status." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/pdufa/apitegromab

```bibtex
@misc{secapidev_pdufa_apitegromab_20261116,
  title        = {ISEMBYLD (apitegromab) PDUFA date and FDA approval status},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/pdufa/apitegromab}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_pdufa_apitegromab_20261116","title":"ISEMBYLD (apitegromab) PDUFA date and FDA approval status","publisher":"sec-api.dev","URL":"https://sec-api.dev/pdufa/apitegromab","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
